Ingredients | Amount Per Serving |
---|---|
(Alkanna tinctoria )
(root)
|
3 Gram(s) |
Below is general information about the effectiveness of the known ingredients contained in the product Alkanet Root Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Alkanet Root Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
LIKELY UNSAFE ...when products containing hepatotoxic pyrrolizidine alkaloid (PA) constituents are used orally. Repeated exposure to low concentrations of hepatotoxic PAs can cause severe veno-occlusive disease. Hepatotoxic PAs might also be carcinogenic and mutagenic (12841,12842). Tell patients not to use alkanna preparations that are not certified and labeled as hepatotoxic PA-free. ...when products containing hepatotoxic PAs are used topically on abraded or broken skin. Absorption of hepatotoxic PAs through broken skin can lead to systemic toxicities (12841). Tell patients not to use topical alkanna preparations that are not certified and labeled as hepatotoxic PA-free. There is insufficient reliable information available about the safety of PA-free alkanna when used orally or topically on unbroken skin.
PREGNANCY AND LACTATION: LIKELY UNSAFE
when alkanna preparations containing hepatotoxic pyrrolizidine alkaloids (PAs) are used orally.
PAs might be teratogenic and hepatotoxic (12841,12842). There is insufficient reliable information available about the safety of alkanna products that do not contain hepatotoxic PAs when used during pregnancy and lactation; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Alkanet Root Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Hepatotoxic pyrrolizidine alkaloids (PAs) are substrates of cytochrome P450 3A4 (CYP3A4) (12841,12860). Theoretically, drugs that induce CYP3A4 might increase the conversion of PAs to toxic metabolites. Some drugs that induce CYP3A4 include carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), and others.
|
Below is general information about the adverse effects of the known ingredients contained in the product Alkanet Root Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally, the major concern with alkanna is its pyrrolizidine alkaloid (PA) content.
These constituents are hepatotoxic, pneumotoxic, carcinogenic, and mutagenic (12841,12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021). Sub-acute veno-occlusive disease can cause vague symptoms, including colicky pains, vomiting, diarrhea, and ascites within several days; persistent liver enlargement occurs within a few weeks (4021,12842).
Topically, PAs can be absorbed through the broken skin. Absorption of PAs can lead to systemic toxicities (12841).
There is currently a limited amount of information available about the adverse effects of PA-free alkanna.
Hepatic ...Orally and topically, alkanna might cause toxicity. The major concern with alkanna use is its hepatotoxic pyrrolizidine alkaloid (PA) content (12841,12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021). Sub-acute veno-occlusive disease can cause vague symptoms, including colicky pains, vomiting, diarrhea, and ascites within several days; persistent liver enlargement occurs within a few weeks (4021,12842).
Oncologic ...Orally and topically, alkanna might cause toxicity. The major concern with alkanna is its pyrrolizidine alkaloid (PA) content. These constituents are carcinogenic and mutagenic (12841,12842).
Pulmonary/Respiratory ...Orally and topically, alkanna might cause toxicity. The major concern with alkanna use is its pyrrolizidine alkaloid (PA) content. These constituents are pneumotoxic (12841,12842).